Last reviewed · How we verify
NCT03656614
Reversal of Residual Neuromuscular Blockade at Train-of-four Ratio 0.3 With Sugammadex and Neostigmine
trial testing Sugammadex in Neuromuscular Blockade in 121 participants. Completed in 30 June 2019.
28 June 2019
Quick facts
| Lead sponsor | Guangzhou General Hospital of Guangzhou Military Command |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 121 |
| Start date | 26 July 2018 |
| Primary completion | 28 June 2019 |
| Estimated completion | 30 June 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Sugammadex — full drug profile →
- Neostigmine (NEOSTIGMINE) — full drug profile →
- Saline 0.9% — full drug profile →
Conditions studied
- Neuromuscular Blockade — all drugs for Neuromuscular Blockade →
Sponsor
Guangzhou General Hospital of Guangzhou Military Command
Who can join
Adults 18 to 65, any sex, with Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to estimate the optimal dose of sugammadex and neostigmine reversal of a vecuronium-induced residual neuromuscular block at train-of-four ratio 0.3.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Required dose of sugammadex or neostigmine for reversal of vecuronium-induced shallow residual neuromuscular block at a train-of-four ratio of 0.3.
He J, He H, Li X, Sun M, et al · · 2022 · cited 6× · PMID 34435439 · DOI 10.1111/cts.13143
Verify or expand the search:
- PubMed search for NCT03656614
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sugammadex
Trials testing the same drug.
- NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
- NCT07271875 — Neuromuscular Blocking Agents on Gastrointestinal Function Following Colorectal Surgery · Phase 3 · not yet recruiting
- NCT07309393 — Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function · NA · recruiting
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT06575036 — Sugammadex Dose Finding Under Two Years Old · Phase 2 · not yet recruiting
Other recruiting trials for Neuromuscular Blockade
Currently open trials in the same condition.
- NCT07203287 — Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease · Phase 4 · recruiting
- NCT06945341 — International Focus Group Discussion on Neuromuscular Monitoring. · recruiting
- NCT06948409 — NMBA Reversal and Postoperative Urinary Retention · active not recruiting
- NCT07003061 — Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery · recruiting
- NCT06679569 — Deep Neuromuscular Blockade on Postoperative Pain · NA · recruiting
Other Guangzhou General Hospital of Guangzhou Military Command trials
Trials by the same sponsor.
- NCT07462949 — A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhi · NA · completed
- NCT07145697 — The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness · Phase 4 · recruiting
- NCT05187455 — Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantat · Phase 4 · unknown
- NCT05202899 — Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniot · Phase 4 · unknown
- NCT04794673 — Cortex Motor Function Reorganization in Stroke Patients · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03656614 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou General Hospital of Guangzhou Military Command
- Last refreshed: 11 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03656614.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing